Eiko Lifesciences Ltd 13 Nov 2026 12:00 AM
Eiko LifeSciences forms joint venture Oval Eiko Resources for Compressed Bio Gas production,
Eiko LifeSciences Limited announced the incorporation of Oval Eiko Resources Private Limited, a joint venture between its wholly-owned subsidiary, Eiko Scientific Solutions LLP, and Oval Projects Engineering Limited, with each holding 50% of the share capital. The new company, incorporated on November 12, 2026, will focus on renewable energy, specifically Compressed Bio Gas production and distribution, and has an authorized and paid-up share capital of Rs 5,00,000. Eiko LifeSciences stated the joint venture aims to diversify its specialty chemicals and API business into the renewable energy sector, and the transaction qualifies as a related party transaction conducted at arm’s length.
Eiko Lifesciences Ltd 06 Nov 2026 12:00 AM
Eiko Lifesciences Ltd consolidated sales up 5.79% on year in Q3FY2026, net profit inched up 3.31%,
Eiko Lifesciences Ltd share price gained 1.24% to Rs 51.44 after the company`s net profit grew slightly 3.31% to Rs 1.56 crore, while revenue from operations slightly gained 5.79% to Rs 17.72 crore in Q3FY26 over Q2FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.72 lakh crore, easing 8.53%. It has improved by 3.85% over last one week and edged lower by 5.28% in last one month while the market capitalization of Eiko Lifesciences Ltd has marginally improved by 1.41% and 7.95% in the same period respectively. Profit before tax (PBT) of Eiko Lifesciences Ltd stood at Rs 2.06 crore in Q3 FY26, surging by 20.47% year-on-year, and gaining 3.00% quarter-on-quarter. EBITDA came in at Rs 2 crore, expanding by 33.11% YoY and rallying 32.24% sequentially. Total expenses grew marginally by 4.45% to Rs 15.74 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 13.22 crore, slightly declining by 5.16% YoY, while employee benefits expense was at Rs 0.2 crore, remaining flat YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 39.96% to Rs 52.71 crore, while net profit jumped 129.31% to Rs 5.32 crore, compared to previous TTM. EBITDA surged by 132% to Rs 6.47 crore, and PBT surged 132.68% to Rs 7.12 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 2.28 crore in FY26, as against Rs 2.78 crore in FY25. Eiko Lifesciences Ltd plunged by 10.52% in last one year, underperforming the benchmark BSE Sensex which has slipped by 4.80% during the same period.
Eiko Lifesciences Ltd 24 Sep 2026 12:00 AM
Eiko LifeSciences halts trading for insiders pending quarterly results announcement,
Eiko LifeSciences Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after a board meeting to approve the un-audited standalone and consolidated financial results for the quarter ended September 30, 2026, the company said in a filing to the BSE Limited.
Eiko Lifesciences Ltd 18 Aug 2026 12:00 AM
Eiko LifeSciences allotted shares to Bhavesh Tanna and V Square Pharmachem for Rs 1.26 crore,
Eiko LifeSciences Limited announced the allotment of 3,05,000 equity shares on the conversion of an equal number of warrants, according to a regulatory filing on Tuesday. The shares were issued at a price of Rs 55 per share, including a premium of Rs 45, to Bhavesh Dhirajlal Tanna and V Square Pharmachem Private Limited, who received the shares on preferential basis after paying Rs 41.25 per warrant. The total amount received from the allotment was Rs 1,25,81,250, increasing the company`s issued, subscribed, and paid-up equity share capital to Rs 14,65,08,540, consisting of 1,46,50,854 fully paid-up equity shares.
Eiko Lifesciences Ltd 12 Aug 2026 12:00 AM
Eiko Lifesciences Ltd consolidated sales down 8.67% on year in Q2FY2026, net profit saw a marginal increase of 0.67%,
Eiko Lifesciences Ltd share price ticked higher by 1.42% to Rs 49.86 after the company`s net profit saw a mild growth of 0.67% to Rs 1.51 crore, while revenue from operations eased by 8.67% to Rs 16.75 crore in Q2FY26 over Q1FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.14 lakh crore, expanding by 15.05%. It has marginally improved by 1.63% over last one week and rose by 11.57% in last one month while the market capitalization of Eiko Lifesciences Ltd has softened by 1% and 0.47% in the same period respectively. Profit before tax (PBT) of Eiko Lifesciences Ltd stood at Rs 2.0 crore in Q2 FY26, surging by 36.05% year-on-year, and slipping 0.99% quarter-on-quarter. EBITDA came in at Rs 2 crore, rallying 22.58% YoY and crashing by 29.30% sequentially. Total expenses slightly declined by 7.60% to Rs 15.07 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 13.94 crore, contracting by 16.33% YoY, while employee benefits expense was at Rs 0.2 crore, slipping by 4.76% YoY. For the TTM ended FY26, revenue from operations jumped by 263.86% to Rs 37.66 crore, while net profit plunged by 164.09% to Rs 2.32 crore, compared to previous TTM. EBITDA saw a sharp decline of 531% to Rs 2.04 crore, and PBT tanked by 162.07% to Rs 3.06 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 2.78 crore in FY26, as against Rs 0.33 crore in FY25. Eiko Lifesciences Ltd dropped 7.32% in last one year, significantly underperforming the benchmark BSE Sensex which has eased by 3.04% during the same period.
Subscribe for our
newsletter
Open Account Now